扩散加权成像对索拉非尼治疗大鼠肝癌疗效的评估  

Assessment of the therapeutic effects of sorafenib for hepatoma in rats with diffusion-weighted imaging

作　　者：刘响[1] 时高峰[1] 王琦[1] 王丽佳[1] 李月考[1] 

机构地区：[1]河北医科大学第四医院CT室,河北石家庄050011

出　　处：《实用放射学杂志》2014年第11期1917-1920,共4页Journal of Practical Radiology

摘　　要：目的扩散加权成像（DWI）评估索拉非尼治疗大鼠肝癌的疗效。方法造模成功的Wistar大鼠分为实验组及对照组，分别给予索拉非尼及生理盐水灌胃治疗，连续21d。治疗前后行MRI检查。观察2组大鼠治疗前后肿瘤大小、ADC值的变化。检查结束后，处死大鼠行病理学检查并进行相关性分析。结果①实验组治疗后肿瘤变小。②实验组各个b值下，治疗后ADC值增大。b值为50s／mm^2时，治疗前后ADC值的差值最大，实验组与对照组治疗前后ADC值的差值的差距最大。③HE染色显示实验组治疗后肿瘤出现灶性坏死。实验组治疗后肿瘤血管密度减低，VEGF染色呈低表达。MVD与VEGF与ADC值的变化具有相关性。结论索拉非尼治疗大鼠肝癌有效，DWI成像能客观评估索拉非尼治疗大鼠肝癌的有效性。Objective To evaluate the therapeutic effect of sorafenib for hepatocellular carcinoma in rats by using diffusion-weighted imaging （DWI）. Methods Wistar rats were divided into an experimental group （n= 30） and a control group （n= 10）. The rats were gavaged with sorafenib and saline for 21 days respectively and then were scanned by MRI before and after treatment. The changes of tumors＇ size and the AOC values before and after treatment in two groups were observed, After the examination, the rats were killed for pathological results. Results In the experimental group, the size of tumor became smaller after treatment, however the AOC value was opposite under each b value. When the b value was set at 50 s/mm^2, the difference in AOC values and the gap between AOC values of difference between experimental and control groups were the largest. HE staining showed focal necrosis in the tumor after treatment. Significantly decreased MVO and low VEGF expression were showed after treatment. The correlation between MVO, VEGF and the changes of the AOC values was also showed. Conclusion Sorafenib may treat liver cancer effectively and its therapeutic effect can be assessed by DWI well.

关 键 词：肝癌 大鼠 扩散加权成像 索拉非尼 表观扩散系数 

分 类 号：R735.7[医药卫生—肿瘤] R332[医药卫生—临床医学]